Tomorrow’s cure lies not in a universal pill, but within our own genetic code.
— Jim Carroll
The opportunity
Enable highly personalized disease risk assessment, tailor preventative strategies based on an individual’s genetic makeup, and optimize drug selection and dosage to maximize efficacy and minimize adverse effects.
From “Decoding Tomorrow: 30 Megatrends - #12 Personalized Medicine: “Tomorrow’s cure lies not in a universal pill, but within our own genetic code.”” (July 2025)
The first is Personalized Medicine , which uses an individual’s unique genomic, environmental, and lifestyle information to guide decisions for prevention, diagnosis, and treatment of disease. It’s based on the idea that because no two individuals are the same, they should not receive the same healthcare.
While we’ve been talking about this capability for years, this theoretical promise of personalized medicine is rapidly translating from theory to therapy. It is making a tangible clinical impact across a growing number of medical specialties. From optimizing drug prescriptions to transforming cancer treatment and offering new hope for rare diseases, the application of genomic and molecular insights is fundamentally changing how clinicians prevent, diagnose, and manage illness.
A prime example of this is Pharmacogenomics (PGx), the study of how an individual’s genetic makeup influences their response to medications. Instead of the traditional one-size-fits-all approach, genetic testing can identify variants affecting drug metabolism. This allows for personalized dosing to determine the optimal drug and dose based on a person’s unique genetic profile. As studies indicate that more than 98% of people may carry at least one such variant, PGx is one of the most broadly applicable pillars of personalized medicine.
From “Megatrends One Year Later – #12: Personalized Medicine – What I Predicted, and What’s Actually Happening” (August 2026)
One year ago, in July 2025, I published Megatrend #12: Personalized Medicine as part of my 30 Megatrends series. Time to grade myself.
The one-size-fits-all era in medicine is ending. Treatments, nutrition, and wellness approaches tailored to individual genetic profiles are becoming the standard, not the exception.
“Reading the code” moved just as fast. AI variant-interpretation models are now standard in genomic diagnostics, flagging disease-causing mutations and predicting treatment response before a clinician even opens the chart, and 2026 is being called the year AI stopped being optional in drug discovery — target selection increasingly starts with a model, not a wet lab.
From “23 and Me: Genomic Medicine and Preventative Care” (June 2016)
This includes the acceleration of genomic medicine, and the transition to a system in which we “fix people before they become sick.” Last week, I was the opening keynote speaker for the AGM of the YMCA of Canada, with a talk around the future of fitness and wellness. This included a bit on the impact of genomics, and the nature of the transition which is underway.
Beyond that, I find the entire voyage to be utterly fascinating. Not only did I receive a detailed overview of my genetic risk factors and inherited conditions (i.e. health risks passed down through families such as cystic fibrosis and Tay Sachs disease), I also got some detailed insight into some really quirky things.
The entire field of genomic science is accelerating at a furious pace, particularly as the cost to undertake genetic sequencing starts to approach the cost curve of Moore’s law. There are massive legal, social, ethical, political and other issues that come with the territory.
Read the full pieces on jimcarroll.com:
Decoding Tomorrow: 30 Megatrends - #12 Personalized Medicine: “Tomorrow’s cure lies not in a universal pill, but within our own genetic code.”
Megatrends One Year Later – #12: Personalized Medicine – What I Predicted, and What’s Actually Happening
23 and Me: Genomic Medicine and Preventative Care